Philip Kurle, MD
Neurology · Osage Beach, MONPI 1184692568
Payments from drug & device makers
Across 615 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$727
- UCB, Inc.$662
- Novartis$600
- EMD Serono, Inc.$588
- Biogen$465
- plus $6K from 51 others
What the payments were for
- Speaking & faculty fees$621%
- Food & beverage$10,21698%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$194
- Austedo XR$108
- AIMOVIG$106
- VYVGART HYTRULO$100
How this compares
$10,391 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 53 | $632,532 |
| BriviactBrivaracetam | 317 | $535,353 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 11 | $352,496 |
| TecfideraDimethyl Fumarate | 19 | $238,663 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 44 | $212,189 |
| XcopriCenobamate | 99 | $118,005 |
| IngrezzaValbenazine Tosylate | 15 | $109,045 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $104,776 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $100,617 |
| NuplazidPimavanserin Tartrate | 20 | $90,135 |
| Emgality PenGalcanezumab-Gnlm | 118 | $85,859 |
| Aimovig AutoinjectorErenumab-Aooe | 75 | $64,070 |
| FycompaPerampanel | 36 | $49,610 |
| AptiomEslicarbazepine Acetate | 38 | $49,432 |
| Dimethyl Fumarate | 19 | $42,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $662 | $535,353317 claims |
| BiogenTecfidera, Avonex (4 Pack) | $465 | $343,43831 claims |
| SK Life Science, Inc.Xcopri | $187 | $118,00599 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $160 | $109,04515 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Vyvanse | $68 | $105,19331 claims |
| Acadia Pharmaceuticals IncNuplazid | $237 | $90,13520 claims |
| Eisai Inc.Fycompa | $194 | $49,61036 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $136 | $49,43238 claims |
| AbbVieQulipta, Ubrelvy, Savella | $1,541 | $46,11151 claims |
| PfizerNurtec Odt | $358 | $32,17330 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er | $88 | $22,29625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.
Other neurology in Osage Beach
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
- Siddharth KaulBridgeton$5.7M
- Kenneth SharlinOzark$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.